RQ Bio announces formation of Executive Committee with three expert appointments
Prof. Paul Kellam appointed Chief Scientific Officer (CSO), Dr Mike Westby appointed Chief Operations Officer (COO) and Alison Seekings appointed Chief Financial Officer (CFO)
Appointments come at key time as RQ Bio looks to reinforce its COVID programme, expand its pipeline and kick-off new programmes in other viral diseases following a successful licensing deal with AstraZeneca earlier this year
LONDON, UK, 3rd October 2022 – RQ Biotechnology Limited (“RQ Bio”), the UK-based biotechnology company dedicated to developing treatments and preventative therapies based on potent broad-spectrum monoclonal antibodies (mAbs), today formalises and strengthens its Executive Committee with three new appointments:
Prof. Paul Kellam, co-founder of RQ Bio, Professor of Virus Genomics at Imperial College London and former Vice President of Infectious Diseases & Vaccines at Kymab, appointed as CSO
Dr Mike Westby, co-founder of RQ Bio, former biotech and pharma R&D Executive including at Pfizer and Roche, with first-hand experience of taking novel anti-infectives through to the market, appointed as COO
Alison Seekings, senior finance leader with extensive experience of working at board level with biotechs, chartered accountant, chartered tax adviser, formerly at Deloitte and former partner at Grant Thornton, appointed as CFO
“I am excited and privileged to have the opportunity to work alongside Paul, Mike and Alison, proven leaders in their field who bring tremendous expertise and understanding of mAbs and infectious diseases, as well as extensive experience in drug discovery and building biotech companies,” said Hugo Fry, CEO of RQ Bio. “I look forward to their invaluable contribution as we work together to develop innovative medicines that will have a significant and fast impact for vulnerable patients in areas of current unmet medical and public health need.”
“LifeArc is committed to backing leading UK academics and scientists, and we are proud to have co-founded RQ Bio and to work with this world class executive team,” said Clare Terlouw, Head of LifeArc Ventures and Board Director, RQ Bio. “The RQ team is passionately dedicated to finding new treatments and preventative therapies in areas of high unmet medical and public health need, and we look forward to the next steps in the Company’s growth.”
Enquiries
Information | info@rqbiotechnology.com
rqbiotechnology.com
LinkedIn
Notes to Editors
About RQ Bio
RQ Bio’s mission is to develop medicines based on potent broad-spectrum mAbs to provide instant and long-lasting immunity for vulnerable people at risk of severe disease or death from current and future variants of viral infections. RQ Bio has achieved this by combining innovative excellence in core areas to create a smarter approach to antibody generation. RQ Bio has multiple sources of leads and a deep collaboration with the University of Oxford. RQ Bio was founded by scientific experts, which worked to build a community of infectious disease antibody experts focussed on the development of rapid and efficient delivery of highly potent neutralising antibodies to help support the UK COVID-19 response.